Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jth.15464 http://scihub22266oqcxt.onion/10.1111/jth.15464 34272818!9906358!34272818     free     free     free       J+Thromb+Haemost 2021 ; 19 (10): 2373-2382 Nephropedia Template TP {{tp|p=34272818|t=2021. Heparin - Messias or Verschlimmbesserung?|pdf=|usr=}}{{34272818}} gab.com Text Heparin - Messias or Verschlimmbesserung JO: J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=34272818 #FOAvip A heightened risk of thrombosis noted early on with the severe acute respiratory syndrome coronavirus 2 infection led to the widespread use of heparin anticoagulation in the coronavirus disease 2019 (COVID-19) pandemic. However, reports soon started appearing in the literature where an apparent failure of heparin to prevent thrombotic events was observed in hospitalized patients with this viral infection. In this review, we explore the likely mechanisms for heparin failure with particular relevance to COVID-19. We also explore the role of anti-Xa assays and global hemostatic tests in this context. The current controversy of dosing heparin in this disease is detailed with some possible mechanistic reasons for anticoagulant failure. We hope that lessons learnt from the use of heparin in COVID-19 could assist us in the appropriate use of this anticoagulant in the future. Twit Text FOAVip Heparin - Messias or Verschlimmbesserung ????J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=34272818 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34272818 #FOAvip English Wikipedia <ref>{{Cite pmid|34272818}}</ref> Heparin - Messias or Verschlimmbesserung? #MMPMID34272818 Swan D; Carrier M; Lisman T; Thachil J J Thromb Haemost 2021[Oct]; 19 (10): 2373-2382 PMID34272818show ga A heightened risk of thrombosis noted early on with the severe acute respiratory syndrome coronavirus 2 infection led to the widespread use of heparin anticoagulation in the coronavirus disease 2019 (COVID-19) pandemic. However, reports soon started appearing in the literature where an apparent failure of heparin to prevent thrombotic events was observed in hospitalized patients with this viral infection. In this review, we explore the likely mechanisms for heparin failure with particular relevance to COVID-19. We also explore the role of anti-Xa assays and global hemostatic tests in this context. The current controversy of dosing heparin in this disease is detailed with some possible mechanistic reasons for anticoagulant failure. We hope that lessons learnt from the use of heparin in COVID-19 could assist us in the appropriate use of this anticoagulant in the future. |*COVID-19[MESH] |*Heparin/adverse effects[MESH] |Anticoagulants/adverse effects[MESH] |Humans[MESH] |Pandemics[MESH]Heparin - Messias or Verschlimmbesserung?(epmc).pdf DeepDyve Pubget Overpricing